Skip to main content

PTLD Up for Seronegative Recipients of Epstein-Barr Virus-Seropositive Donor Kidneys

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 5, 2025.

via HealthDay

WEDNESDAY, Feb. 5, 2025 -- Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R−) kidneys have an increased risk for posttransplant lymphoproliferative disorder (PTLD), according to a study published online Jan. 28 in the Annals of Internal Medicine.

Vishnu S. Potluri, M.D., M.P.H., from the Hospital of the University of Pennsylvania, and colleagues conducted a retrospective cohort study to examine the associations between pretransplant EBV D+/R− and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival in adult recipients of kidney transplant.

The final cohort included 104 EBV D+/R− recipients matched to 312 EBV R+ recipients. The researchers found that 50 (48.1 percent) of the EBV D+/R− recipients developed EBV DNAemia, with a median time of 198 days after transplant. At a median of 202 days after transplant, 23 (22.1 percent) EBV D+/R− recipients had PTLD. Higher all-cause graft failure was seen in EBV D+/R− recipients (hazard ratio, 2.21; 95 percent confidence interval, 1.06 to 4.63), and mortality was higher but the increase was not statistically significant (hazard ratio, 2.19; 95 percent confidence interval, 0.94 to 5.13).

"Our findings highlight the need for strategies to attenuate the effect of donor-derived EBV infection among EBV-seronegative recipients and for counseling prospective EBV D+/R− recipients about the elevated risk for early PTLD," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Virtual Reality Training Module May Aid Infection Control Efforts

TUESDAY, June 17, 2025 -- Users report positive experiences and engagement with a virtual reality tool that trains clinicians on core concepts in infection control, including...

2,770 Cases of Arboviral Disease Reported in 48 States and D.C. in 2023

TUESDAY, June 17, 2025 -- In 2023, 48 states and the District of Columbia reported 2,770 human arboviral disease cases, with West Nile Virus (WNV) being the most common, according...

Standard-Criteria Kidney Transplant Offers Clear Survival Benefit Over Continued Dialysis

TUESDAY, June 10, 2025 -- Transplantation with standard-criteria kidney offers a clear survival benefit, but this decreases with age and for those with a history of cardiovascular...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.